News

Final Decision on Alzheimer's Drug Treatment Coverage

The Centers for Medicare & Medicaid Services (CMS) released its final decision on coverage for a new class of drugs addressing the underlying biology of Alzheimer’s disease. We are deeply disappointed with the immediate impact this decision will have on Americans living with Alzheimer’s and their families. Our full statement on the CMS decision is here. As you may recall, the first of these treatments — aducanumab or Aduhuelm — was approved by the U.S. Food and Drug Administration (FDA) last June under the